MEP14408A - 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds - Google Patents

4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Info

Publication number
MEP14408A
MEP14408A MEP-144/08A MEP14408A MEP14408A ME P14408 A MEP14408 A ME P14408A ME P14408 A MEP14408 A ME P14408A ME P14408 A MEP14408 A ME P14408A
Authority
ME
Montenegro
Prior art keywords
compounds
production
pharmaceutical compositions
compositions containing
halogenated
Prior art date
Application number
MEP-144/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Bernd Menzenbach
Walter Elger
Peter Droescher
Alexander Hillisch
Guenter Kaufmann
Hans-Udo Schweikert
Gerd Mueller
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of MEP14408A publication Critical patent/MEP14408A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MEP-144/08A 2000-09-04 2001-08-29 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds MEP14408A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10043846A DE10043846A1 (de) 2000-09-04 2000-09-04 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
PCT/EP2001/009943 WO2002019971A1 (de) 2000-09-04 2001-08-29 4-halogenierte 17-methylensteroide, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Publications (1)

Publication Number Publication Date
MEP14408A true MEP14408A (en) 2010-06-10

Family

ID=7655148

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-144/08A MEP14408A (en) 2000-09-04 2001-08-29 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds

Country Status (29)

Country Link
EP (1) EP1423407B1 (zh)
JP (1) JP2004513084A (zh)
KR (1) KR100530816B1 (zh)
CN (1) CN1262560C (zh)
AT (1) ATE319733T1 (zh)
AU (2) AU1047002A (zh)
BG (1) BG107594A (zh)
BR (1) BR0113618A (zh)
CA (1) CA2421302C (zh)
DE (2) DE10043846A1 (zh)
DK (1) DK1423407T3 (zh)
EA (1) EA006387B1 (zh)
EE (1) EE05186B1 (zh)
ES (1) ES2260294T3 (zh)
HK (1) HK1060135A1 (zh)
HR (1) HRP20030256A2 (zh)
HU (1) HUP0300936A3 (zh)
IL (2) IL154666A0 (zh)
ME (1) MEP14408A (zh)
MX (1) MXPA03001912A (zh)
NO (1) NO325012B1 (zh)
NZ (1) NZ524485A (zh)
PL (1) PL360669A1 (zh)
PT (1) PT1423407E (zh)
RS (1) RS50305B (zh)
SK (1) SK286757B6 (zh)
UA (1) UA74592C2 (zh)
WO (1) WO2002019971A1 (zh)
ZA (1) ZA200301715B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141984A1 (de) 2001-08-28 2003-03-20 Jenapharm Gmbh Neue 17-Methylen-4-azasteroide
US7199115B2 (en) 2004-04-19 2007-04-03 Schering Ag 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them
AT12800U1 (de) * 2007-11-05 2012-11-15 Bayer Schering Pharma Ag Pharmazeutisches Präparat zur Verwendung bei der oralen Kontrazeption von Frauen mit Laktoseintoleranz

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611773A (en) * 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US3146239A (en) * 1957-09-23 1964-08-25 Syntex Corp 4-halo-19-nor-progesterone
US3232960A (en) * 1959-10-08 1966-02-01 Upjohn Co 3-keto-4-fluoro- and 3-keto-4,4-difluorosteroids and process
US3661940A (en) * 1970-04-13 1972-05-09 Sandoz Ag Derivatives of 21-methyl-19-norpregnanes
US4389345A (en) * 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
AU2001268661A1 (en) * 2000-06-27 2002-01-08 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase

Also Published As

Publication number Publication date
KR100530816B1 (ko) 2005-11-25
HUP0300936A2 (hu) 2003-11-28
EP1423407A1 (de) 2004-06-02
AU1047002A (en) 2002-03-22
YU16403A (sh) 2006-05-25
NO20030989L (no) 2003-05-02
SK286757B6 (sk) 2009-05-07
EP1423407B1 (de) 2006-03-08
IL154666A0 (en) 2003-09-17
JP2004513084A (ja) 2004-04-30
ES2260294T3 (es) 2006-11-01
IL154666A (en) 2008-12-29
CA2421302A1 (en) 2003-03-03
NO325012B1 (no) 2008-01-14
ATE319733T1 (de) 2006-03-15
SK2442003A3 (en) 2003-08-05
EA200300322A1 (ru) 2003-10-30
PL360669A1 (en) 2004-09-20
CN1452628A (zh) 2003-10-29
EE200300087A (et) 2005-02-15
WO2002019971A1 (de) 2002-03-14
WO2002019971A9 (de) 2002-08-08
HK1060135A1 (en) 2004-07-30
MXPA03001912A (es) 2004-07-08
NZ524485A (en) 2005-11-25
NO20030989D0 (no) 2003-03-03
CA2421302C (en) 2007-08-14
PT1423407E (pt) 2006-07-31
DK1423407T3 (da) 2006-07-03
BR0113618A (pt) 2003-07-15
CN1262560C (zh) 2006-07-05
RS50305B (sr) 2009-09-08
EE05186B1 (et) 2009-06-15
HRP20030256A2 (en) 2005-10-31
BG107594A (bg) 2003-09-30
UA74592C2 (en) 2006-01-16
DE50109175D1 (de) 2006-05-04
AU2002210470B2 (en) 2006-07-20
DE10043846A1 (de) 2002-04-04
EA006387B1 (ru) 2005-12-29
HUP0300936A3 (en) 2010-01-28
KR20030028836A (ko) 2003-04-10
ZA200301715B (en) 2004-08-13

Similar Documents

Publication Publication Date Title
CY1115477T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
BR112012009306A2 (pt) método para regeneração de mielina em um paciente
NO20020651L (no) Björkebarkbehandling og isolering av naturprodukter fra björkebark
NO20022292L (no) Nye topiske östrogenprogestogenpreparater med systemisk effekt
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
WO2005077968A3 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
MX2019001323A (es) Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico.
SG158916A1 (en) Nitrooxy derivatives op glucocorticoids
MX2019001327A (es) Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido.
DE60330695D1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
Mutiah et al. Cytotoxic effect of crude extract and fraction from Calotropis gigantea leaves on human colon cancer widr cell lines
NO20053626L (no) Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose
HUP9903747A2 (hu) Új eljárás mometazon-furoát előállítására
MEP14408A (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
BR0008437A (pt) Inibidores esteróides de sulfatase e métodos parafabricação e uso dos mesmos
RS90504A (en) C-17 spirolactonization and 6,7 oxidation of steroids
TW200612962A (en) Estriol and estetrol prodrugs
NO20023276L (no) Fremgangsmåter fremstilling av betulinsyre
ZA201908404B (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
AR048829A1 (es) 17alfa - fluoroesteroides con actividad inhibidora de 5 alfa-reductasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades cancerosas influidas por androgenos.
NO20054636L (no) Fremgangsmate for fremstilling av steroidale karbotiosyrederivater og -intermediater
DK1910398T3 (da) 17-alfa-substituerede derivater af estradiol med sårhelende virkning
AR003967A1 (es) Epimeros de (22r)-n-(1,1,1-trifluoro-2-fenilprop-2-il)-3-oxo-4-aza-5alfa- androst-1-eno-17beta-carboxamida, un proceso para su preparacion y unacomposicion farmaceutica que los comprenden.
Ben-juan et al. Hydrogen peroxide induced apoptosis in SV-40 transformed human salivary gland acinar cells
DE502004004976D1 (de) Verwendung eines oxytocin und testosteron oder estradiol enthaltenden gemisches zur behandlung von störungen des psychosozialen erlebens und verhaltens